Molecular target
EGFR (Epidermal Growth Factor Receptor)
Also: ErbB1, HER1 · id EGFR
Receptor tyrosine kinase driving proliferation and survival signaling in many epithelial cancers; the target of EGFR-inhibitor oncology drugs (erlotinib, gefitinib, osimertinib). Multiple dietary polyphenols — notably green-tea EGCG and curcumin — have been investigated in preclinical models for EGFR-pathway modulation (research only; not a treatment claim).
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on EGFR (Epidermal Growth Factor Receptor)
These medications have EGFR (Epidermal Growth Factor Receptor) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on EGFR (Epidermal Growth Factor Receptor)
Each plant below contains a named compound documented to act on EGFR (Epidermal Growth Factor Receptor). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- EGCG (Epigallocatechin gallate)Catechin polyphenol
Most studied catechin; broad antioxidant and anti-inflammatory activity. Also investigated in preclinical cancer models for EGFR / receptor-tyrosine-kinase and anti-angiogenic (VEGF) pathway modulation (research only). High-dose extracts can be hepatotoxic.
- CurcuminPolyphenol (curcuminoid)
Beyond its anti-inflammatory NF-kB/COX/LOX activity, curcumin has been investigated in preclinical cancer models for EGFR-pathway and PI3K–Akt–mTOR signaling inhibition and for anti-angiogenic (VEGF) effects. Research only — not a treatment claim.